Can a new drug Leramistat slow lung function decline for people with idiopathic pulmonary fibrosis?

Upcoming study
Expected to open August 2023
This study is currently recruiting
Expected to close July 2024
This study is closed
This study closed in July 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in July 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

The aim of this study is to investigate the safety and effectiveness of a new drug Leramistat in slowing lung function decline in people living with IPF.


What is involved?

You will be randomly assigned to one of two groups. One group will receive a new drug called Leramistat, and the other group will receive a look alike drug in the form of a placebo. A placebo does not contain any of the active drug ingredients. You and the researchers will not know which group you have been assigned to until after the study has finished.

The researchers will check if you're eligible to take part in the study. This will take around 1 to 4 weeks. During that time you may have tests to look at your lung function, walking distance, and potentially a CT scan.

If you qualify and decide to take part, you will receive either the drug Leramistat or a placebo for 12 weeks. During that time, the researchers will monitor you and you will have additional blood tests and breathing tests to look at your lung function, at the end of the study.

Summary of involvement

Maximum of 24 weeks participation

Taking either the new drug or the placebo for 12 weeks

Breathing tests to look at lung function

Blood tests

Can I take part?

You may be able to take part if you have a diagnosis of IPF and are aged 40 years and over. If you are currently receiving treatment for your IPF, such as the antifibrotic medication nintedanib or pirfenidone, then you must have been on a stable dose for at least 8 weeks.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

• Aged 40 or over.

• Diagnosis of IPF

• Lung function over 45%, measured with a breathing test.

• If medication is being taken, only those on nintedanib or pirfenidone and on a stable dose of either for at least 8 weeks before the study.

• Expected lifespan over 1 year to be able to participate in the study fully

You will not be able to join the study of any of the following applies:

• Emphysema effecting ≥50% of the lungs, or if the emphysema is more extensive than the fibrosis.

• Current or previous history of cancer within the last 5 years

• Abnormal heart rate, blood pressure or ECG during tests at your first visit

• Significant history of strong drug allergies or allergic reactions

• History of chronic or recurring infections

• Diagnosis of severe chronic obstructive pulmonary disease (COPD) or asthma

What difference could taking part make?

Taking part in this study will help researchers to understand if Leramistat could be effective in the treatment of IPF.

Where does the study take place?

Study locations




How to take part

Please speak to your medical team about taking part, or contact the research team directly, to express your interests.

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Modern Biosciences Ltd
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email